Corrigendum: Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms - Viktor Grünwald; Thomas Powles; Masatoshi Eto; Evgeny Kopyltsov; Sun Young Rha; Camillo Porta; Robert Motzer; Thomas E. Hutson; María José Méndez-Vidal; Sung-Hoo Hong; Eric Winquist; Jeffrey C. Goh; et al. (Frontiers in Oncology, 2024)